MINERVA NEUROSCIENCES INC (NERV) Stock News
NASDAQ:NERV - Nasdaq - US6033802058 - Common Stock - Currency: USD
NERV Latest News, Press Relases and Analysis
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences (Nasdaq: NERV) today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024. ...
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
NERV Stock Earnings: Minerva Neurosciences Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Minerva Neurosciences (NASDAQ:NERV) just reported results for the second quarte...
NERV Stock Earnings: Minerva Neurosciences Misses EPS for Q2 2024
NERV stock results show that Minerva Neurosciences missed analyst estimates for earnings per share the second quarter of 2024.
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on...
NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024
NERV stock results show that Minerva Neurosciences beat analyst estimates for earnings per share the first quarter of 2024.
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&P 500 also rose, gaining, 0.04% to 5,071.40.
Minerva stock falls as FDA rejects schizophrenia drug
Minerva Neurosciences (NERV) stock falls as the FDA rejects its schizophrenia drug candidate, roluperidone. Read more here.
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on...